Vientiane, Laos – November 11, 2025 -Lucius Pharmaceutical is focused on providing effective, safe, and reliable medications and services for patients all over the world., today announced LuciRevu (Revumenib) have been approved by the Ministry of Health of Laos. Approved drugs are: Revumenib : sold under the brand name LuciRevu. Revumenib is an anti-cancer medication used for the treatment of acute leukemias harboring lysine methyltransferase 2A gene (KMT2A) rearrangements.It is designed to disrupt the interaction between menin and KMT2A (also known as MLL), which plays a role in the pathogenesis of these leukemias. LuciRevu is available in three strengths: 25 mg, 110 mg, and 160 mg.  It is taken by mouth.  Acute myeloid … Continue reading LUCIUS Pharmaceutical announces the approval LuciRevu in Laos